deferoxamine has been researched along with Injury, Myocardial Reperfusion in 60 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The deferoxamine dose was five times greater than the maximally tolerated dose of free deferoxamine." | 2.67 | High-dose iron-chelator therapy during reperfusion with deferoxamine-hydroxyethyl starch conjugate fails to reduce canine infarct size. ( Hallaway, PE; Hedlund, BE; Horwitz, LD; Lesnefsky, EJ, 1990) |
| "Deferoxamine was given both intravenously (30 mg/kg of body weight, starting 30 minutes before and ending 30 minutes after bypass) and as an additive to the cardioplegic solution (250 mg/L)." | 2.66 | Deferoxamine reduces neutrophil-mediated free radical production during cardiopulmonary bypass in man. ( Bellucci, S; Jaillon, P; Lorente, P; Menasché, P; Pasquier, C; Piwnica, A, 1988) |
| "Isoflurane has been shown to mimic ischaemic preconditioning (IPC)." | 1.33 | Ischaemic preconditioning but not isoflurane prevents post-ischaemic production of hydroxyl radicals in a canine model of ischaemia-reperfusion. ( Berenshtein, E; Chevion, M; Drenger, B; Elami, A; Gozal, Y; Kitrossky, N, 2005) |
| "Oxygen delivery was maintained during hypoxemia by increasing cardiopulmonary bypass flow and hematocrit level." | 1.29 | Studies of hypoxemic/reoxygenation injury: without aortic clamping. IV. Role of the iron-catalyzed pathway: deferoxamine. ( Buckberg, GD; Ihnken, K; Morita, K; Sherman, MP; Young, HH, 1995) |
| "Deferoxamine (100 microM) was added to the perfusate just prior to reperfusion in group I, and 3 min after the start of reperfusion in group II." | 1.29 | Deferoxamine reduces the reperfusion injury in isolated neonatal rabbit hearts after hypothermic preservation. ( Abe, T; Akita, T; Kamiya, K; Katoh, S; Kodama, I; Toyama, J, 1993) |
| "Salicylic acid was used as the probe for ." | 1.28 | Quantification of hydroxyl radical and its lack of relevance to myocardial injury during early reperfusion after graded ischemia in rat hearts. ( Ashraf, M; Onodera, T; Takemura, G, 1992) |
| "The treatment with catechol, mimosine, or deferoxamine reduced the maximum intensity of DMPO-OH signal to about one third of control." | 1.28 | Protective action of iron-chelating agents (catechol, mimosine, deferoxamine, and kojic acid) against ischemia-reperfusion injury of isolated neonatal rabbit hearts. ( Abe, T; Akita, T; Kamiya, K; Katoh, S; Kodama, I; Toyama, J, 1992) |
| "Deferoxamine pretreatment improved survival at each dose from a control value of 44% to 71% and 72% (p less than 0." | 1.28 | Iron chelation in myocardial preservation after ischemia-reperfusion injury: the importance of pretreatment and toxicity. ( Clark, RE; DeBoer, DA, 1992) |
| "Deferoxamine (50 mumol/kg) was given to one group with the hypertrophied hearts during the first 10 minutes of reperfusion." | 1.28 | Deferoxamine fails to improve postischemic cardiac function in hypertrophied hearts. ( del Nido, PJ; Feinberg, H; Jimenez, E; Levitsky, S; Nakamura, H; Sarin, M, 1990) |
| " Thus open-chest dogs undergoing a 15-min coronary occlusion and 4 h of reperfusion were given one of the following intracoronary infusions: desferrioxamine (DF) beginning 2 min before reperfusion (group I), DF beginning 1 min after reperfusion (group II), iron-loaded DF in dosage identical to group I (group III), or vehicle (controls, group IV)." | 1.28 | Iron-mediated radical reactions upon reperfusion contribute to myocardial "stunning". ( Bolli, R; Jeroudi, MO; Lai, EK; Li, XY; McCay, PB; Patel, BS; Triana, JF, 1990) |
| "Pretreatment with deferoxamine or apotransferrin attenuated this permeability increase (sigma = 0." | 1.28 | Role of iron in postischemic microvascular injury. ( Carden, DL; Granger, DN; Grisham, MB; Korthuis, RJ; Smith, JK, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (11.67) | 18.7374 |
| 1990's | 40 (66.67) | 18.2507 |
| 2000's | 5 (8.33) | 29.6817 |
| 2010's | 4 (6.67) | 24.3611 |
| 2020's | 4 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, T | 1 |
| He, Q | 1 |
| Cheng, C | 1 |
| Li, H | 1 |
| Liang, L | 1 |
| Zhang, G | 1 |
| Su, C | 1 |
| Xiao, Y | 1 |
| Bradley, J | 1 |
| Peberdy, MA | 1 |
| Ornato, JP | 1 |
| Tang, W | 1 |
| Chen, Y | 1 |
| Li, X | 1 |
| Wang, S | 1 |
| Miao, R | 1 |
| Zhong, J | 1 |
| Tang, LJ | 2 |
| Luo, XJ | 2 |
| Tu, H | 2 |
| Chen, H | 1 |
| Xiong, XM | 2 |
| Li, NS | 1 |
| Peng, J | 2 |
| Zhou, YJ | 1 |
| Zhang, XJ | 1 |
| Ali Sheikh, MS | 1 |
| Zhang, JJ | 1 |
| Yuan, C | 2 |
| Xie, P | 1 |
| Yang, L | 1 |
| Talaiti, A | 1 |
| Wu, JJ | 1 |
| Yu, J | 1 |
| Yu, T | 1 |
| Wang, HY | 1 |
| Huang, B | 1 |
| Wu, Q | 1 |
| Maimaitili, Y | 1 |
| Wang, J | 1 |
| Ma, HP | 1 |
| Yang, YN | 1 |
| Zheng, H | 1 |
| Wang, H | 1 |
| Yuan, Z | 1 |
| Zieger, MA | 1 |
| Gupta, MP | 1 |
| Koch, A | 1 |
| Loganathan, S | 1 |
| Radovits, T | 1 |
| Sack, FU | 1 |
| Karck, M | 1 |
| Szabó, GB | 1 |
| Kovacevic, Z | 1 |
| Yu, Y | 1 |
| Richardson, DR | 1 |
| Dendorfer, A | 1 |
| Heidbreder, M | 1 |
| Hellwig-Bürgel, T | 1 |
| Jöhren, O | 1 |
| Qadri, F | 1 |
| Dominiak, P | 1 |
| Paraskevaidis, IA | 1 |
| Iliodromitis, EK | 1 |
| Vlahakos, D | 1 |
| Tsiapras, DP | 1 |
| Nikolaidis, A | 1 |
| Marathias, A | 1 |
| Michalis, A | 1 |
| Kremastinos, DT | 1 |
| Gozal, Y | 1 |
| Chevion, M | 1 |
| Elami, A | 1 |
| Berenshtein, E | 1 |
| Kitrossky, N | 1 |
| Drenger, B | 1 |
| Morita, K | 1 |
| Ihnken, K | 1 |
| Buckberg, GD | 1 |
| Sherman, MP | 1 |
| Young, HH | 1 |
| Daniels, S | 1 |
| Duncan, CJ | 1 |
| Hansen, PR | 1 |
| Stawski, G | 1 |
| Collis, CS | 1 |
| Davies, MJ | 3 |
| Rice-Evans, C | 1 |
| Euler, DE | 1 |
| Liu, LL | 1 |
| Zhao, BL | 1 |
| Sellke, FW | 1 |
| Shafique, T | 1 |
| Ely, DL | 1 |
| Weintraub, RM | 1 |
| Watanabe, BI | 1 |
| Limm, W | 1 |
| Suehiro, A | 1 |
| Suehiro, G | 1 |
| Premaratne, S | 1 |
| McNamara, JJ | 1 |
| Pucheu, S | 1 |
| Coudray, C | 1 |
| Tresallet, N | 1 |
| Favier, A | 1 |
| de Leiris, J | 1 |
| Hedlund, BE | 2 |
| Hallaway, PE | 2 |
| Patterson, E | 1 |
| Katoh, S | 3 |
| Toyama, J | 3 |
| Kodama, I | 3 |
| Kamiya, K | 2 |
| Akita, T | 3 |
| Abe, T | 3 |
| Chagas, AC | 1 |
| Pileggi, F | 1 |
| Lopes, EA | 1 |
| Da-Luz, PL | 1 |
| Bel, A | 1 |
| Martinod, E | 1 |
| Menasché, P | 3 |
| Atanasiu, R | 1 |
| Dumoulin, MJ | 1 |
| Chahine, R | 1 |
| Mateescu, MA | 1 |
| Nadeau, R | 1 |
| Nicholson, SC | 1 |
| Squier, M | 1 |
| Ferguson, DJ | 1 |
| Nagy, Z | 1 |
| Westaby, S | 1 |
| Evans, RD | 1 |
| Shadid, M | 1 |
| Van Bel, F | 1 |
| Steendijk, P | 1 |
| Dorrepaal, CA | 1 |
| Moison, R | 1 |
| Van Der Velde, ET | 1 |
| Baan, J | 1 |
| Powell, SR | 1 |
| Gurzenda, EM | 1 |
| Wingertzahn, MA | 1 |
| Wapnir, RA | 1 |
| Hansen, TN | 1 |
| Haworth, RA | 1 |
| Southard, JH | 1 |
| Takemura, G | 1 |
| Onodera, T | 1 |
| Ashraf, M | 1 |
| Reznick, AZ | 1 |
| Kagan, VE | 1 |
| Ramsey, R | 1 |
| Tsuchiya, M | 1 |
| Khwaja, S | 1 |
| Serbinova, EA | 1 |
| Packer, L | 1 |
| Mousa, SA | 1 |
| Ritger, RC | 1 |
| Smith, RD | 1 |
| DeBoer, DA | 1 |
| Clark, RE | 1 |
| Nakamura, H | 2 |
| del Nido, PJ | 3 |
| Jimenez, E | 2 |
| Sarin, M | 2 |
| Feinberg, H | 2 |
| Levitsky, S | 3 |
| Mergner, GW | 1 |
| Weglicki, WB | 1 |
| Kramer, JH | 1 |
| Lesnefsky, EJ | 1 |
| Horwitz, LD | 1 |
| Flaherty, JT | 2 |
| Zweier, JL | 2 |
| Reddy, BR | 2 |
| Wynne, J | 1 |
| Kloner, RA | 2 |
| Przyklenk, K | 2 |
| Williams, RE | 1 |
| Kobayashi, S | 1 |
| Tadokoro, H | 1 |
| Wakida, Y | 1 |
| Kar, S | 1 |
| Nordlander, R | 1 |
| Haendchen, RV | 1 |
| Corday, E | 1 |
| McCord, JM | 2 |
| Turner, JJ | 1 |
| Rice-Evans, CA | 1 |
| Newman, ES | 1 |
| Shuter, SL | 1 |
| Garlick, PB | 1 |
| Hearse, DJ | 3 |
| Slater, TF | 1 |
| van Jaarsveld, H | 3 |
| Potgieter, GM | 3 |
| Barnard, SP | 2 |
| Potgieter, S | 1 |
| Bolli, R | 1 |
| Patel, BS | 1 |
| Jeroudi, MO | 1 |
| Li, XY | 1 |
| Triana, JF | 1 |
| Lai, EK | 1 |
| McCay, PB | 1 |
| Galiñanes, M | 1 |
| Kuyl, JM | 2 |
| Barnard, HC | 1 |
| Groenewald, AJ | 1 |
| Maxwell, MP | 1 |
| Yellon, DM | 1 |
| Smith, JK | 1 |
| Carden, DL | 1 |
| Grisham, MB | 1 |
| Granger, DN | 1 |
| Korthuis, RJ | 1 |
| Illes, RW | 1 |
| Silverman, NA | 1 |
| Krukenkamp, IB | 1 |
| Pasquier, C | 1 |
| Bellucci, S | 1 |
| Lorente, P | 1 |
| Jaillon, P | 1 |
| Piwnica, A | 2 |
| Russell, WJ | 1 |
| Grousset, C | 1 |
| Gauduel, Y | 1 |
| Mouas, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery: Proposal for Pilot Investigation[NCT02519335] | Phase 1 | 12 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to PI no longer at this facility) | ||
| Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery[NCT04997291] | Phase 1 | 12 participants (Anticipated) | Interventional | 2021-04-09 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for deferoxamine and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Targeting Iron Metabolism and Ferroptosis as Novel Therapeutic Approaches in Cardiovascular Diseases.
Topics: Cardiovascular Diseases; Deferoxamine; Ferroptosis; Humans; Hypertension; Iron; Lipid Peroxidation; | 2023 |
High-dose systemic iron chelation attenuates reperfusion injury.
Topics: Animals; Deferoxamine; Dogs; Iron; Iron Chelating Agents; Myocardial Ischemia; Myocardial Reperfusio | 1993 |
Myocardial protection in the occlusion/reperfusion dog model: the role of ischemic necrosis vs reperfusion injury.
Topics: Animals; Coronary Vessels; Deferoxamine; Disease Models, Animal; Dogs; Free Radicals; Iron; Myocardi | 1995 |
Cardioprotective effect of desferrioxamine.
Topics: Animals; Cardiopulmonary Bypass; Deferoxamine; Free Radicals; Humans; Iron Chelating Agents; Myocard | 1996 |
Role of oxygen radicals in myocardial reperfusion injury: experimental and clinical evidence.
Topics: Animals; Deferoxamine; Free Radicals; Humans; Lipid Peroxidation; Myocardial Reperfusion Injury; Neu | 1991 |
Free radicals, myocytes and reperfusion injury.
Topics: Animals; Deferoxamine; Free Radicals; Humans; In Vitro Techniques; Myocardial Reperfusion Injury; My | 1990 |
3 trials available for deferoxamine and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Deferoxamine infusion during coronary artery bypass grafting ameliorates lipid peroxidation and protects the myocardium against reperfusion injury: immediate and long-term significance.
Topics: Coronary Artery Bypass; Coronary Artery Disease; Deferoxamine; Echocardiography, Transesophageal; Hu | 2005 |
High-dose iron-chelator therapy during reperfusion with deferoxamine-hydroxyethyl starch conjugate fails to reduce canine infarct size.
Topics: Analysis of Variance; Animals; Deferoxamine; Dogs; Dose-Response Relationship, Drug; Double-Blind Me | 1990 |
Deferoxamine reduces neutrophil-mediated free radical production during cardiopulmonary bypass in man.
Topics: Cardiopulmonary Bypass; Deferoxamine; Female; Free Radicals; Humans; Male; Middle Aged; Myocardial R | 1988 |
Deferoxamine reduces neutrophil-mediated free radical production during cardiopulmonary bypass in man.
Topics: Cardiopulmonary Bypass; Deferoxamine; Female; Free Radicals; Humans; Male; Middle Aged; Myocardial R | 1988 |
Deferoxamine reduces neutrophil-mediated free radical production during cardiopulmonary bypass in man.
Topics: Cardiopulmonary Bypass; Deferoxamine; Female; Free Radicals; Humans; Male; Middle Aged; Myocardial R | 1988 |
Deferoxamine reduces neutrophil-mediated free radical production during cardiopulmonary bypass in man.
Topics: Cardiopulmonary Bypass; Deferoxamine; Female; Free Radicals; Humans; Male; Middle Aged; Myocardial R | 1988 |
51 other studies available for deferoxamine and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
UAMC-3203 or/and Deferoxamine Improve Post-Resuscitation Myocardial Dysfunction Through Suppressing Ferroptosis in a Rat Model of Cardiac Arrest.
Topics: Animals; Cardiopulmonary Resuscitation; Cyclohexylamines; Deferoxamine; Disease Models, Animal; Ferr | 2022 |
Ferroptosis occurs in phase of reperfusion but not ischemia in rat heart following ischemia or ischemia/reperfusion.
Topics: Animals; Biomarkers; Coenzyme A Ligases; Creatine Kinase; Deferoxamine; Ferroptosis; Iron; Ischemia; | 2021 |
Combination of ponatinib with deferoxamine synergistically mitigates ischemic heart injury via simultaneous prevention of necroptosis and ferroptosis.
Topics: Animals; Cell Line; Deferoxamine; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; | 2021 |
Deferoxamine-activated hypoxia-inducible factor-1 restores cardioprotective effects of sevoflurane postconditioning in diabetic rats.
Topics: Anesthetics, Inhalation; Animals; Deferoxamine; Diabetes Mellitus, Experimental; Gene Expression Reg | 2017 |
Ginsenoside Rg1 inhibits myocardial ischaemia and reperfusion injury
Topics: Animals; Apoptosis; Caspase 3; Caspase 9; Deferoxamine; Diabetes Mellitus, Experimental; Extracellul | 2019 |
Hypothermic preconditioning of endothelial cells attenuates cold-induced injury by a ferritin-dependent process.
Topics: Cell Proliferation; Cells, Cultured; Cold Temperature; Coronary Vessels; Deferoxamine; Endothelial C | 2009 |
Deferoxamine, the newly developed iron chelator LK-614 and N-alpha-acetyl-histidine in myocardial protection.
Topics: Animals; Cold Ischemia; Deferoxamine; Glucose; Heart Transplantation; Histidine; Hydroxamic Acids; I | 2010 |
Chelators to the rescue: different horses for different courses!
Topics: Aldehydes; Animals; Deferoxamine; Humans; Hydrazones; Iron Chelating Agents; Iron Overload; Isoniazi | 2011 |
Deferoxamine induces prolonged cardiac preconditioning via accumulation of oxygen radicals.
Topics: Aldehyde Reductase; Alkaloids; Animals; Aryl Hydrocarbon Receptor Nuclear Translocator; Basic Helix- | 2005 |
Ischaemic preconditioning but not isoflurane prevents post-ischaemic production of hydroxyl radicals in a canine model of ischaemia-reperfusion.
Topics: Anesthetics, Inhalation; Animals; Antidotes; Blood Pressure; Catechols; Deferoxamine; Dogs; Heart Ra | 2005 |
Studies of hypoxemic/reoxygenation injury: without aortic clamping. IV. Role of the iron-catalyzed pathway: deferoxamine.
Topics: Alkadienes; Animals; Cardiopulmonary Bypass; Creatine Kinase; Deferoxamine; Heart; Hypoxia; Iron; Li | 1995 |
Are oxygen radicals implicated in the calcium paradox of the rat heart?
Topics: Animals; Caffeine; Calcium; Catalase; Creatine Kinase; Deferoxamine; Dinitrophenols; Free Radical Sc | 1994 |
Neutrophil mediated damage to isolated myocytes after anoxia and reoxygenation.
Topics: alpha-Macroglobulins; Animals; Antibodies, Monoclonal; Antigens, CD; Arginine; Catalase; CD18 Antige | 1994 |
Comparison of N-methyl hexanoylhydroxamic acid, a novel antioxidant, with desferrioxamine and N-acetyl cysteine against reperfusion-induced dysfunctions in isolated rat heart.
Topics: Acetylcysteine; Animals; Antioxidants; Cardiovascular Agents; Deferoxamine; Heart; Heart Rate; Hydro | 1993 |
Role of oxygen-derived free radicals in canine reperfusion arrhythmias.
Topics: Animals; Antioxidants; Arrhythmias, Cardiac; Blood Pressure; Catalase; Coronary Circulation; Coronar | 1995 |
[A study on the protective effect of metallic chelators on ischemia-reperfusion injury of isolated rat heart].
Topics: Animals; Creatine Kinase; Deferoxamine; Female; Free Radical Scavengers; In Vitro Techniques; Male; | 1993 |
Coronary endothelial injury after cardiopulmonary bypass and ischemic cardioplegia is mediated by oxygen-derived free radicals.
Topics: Animals; Cardiopulmonary Bypass; Coronary Vessels; Deferoxamine; Endothelium, Vascular; Free Radical | 1993 |
Failure of deferoxamine to reduce myocardial infarct size in a primate model of ischemia-reperfusion injury.
Topics: Animals; Deferoxamine; Disease Models, Animal; Electrocardiography; Female; Free Radicals; Hydroxyl | 1993 |
Effect of iron overload in the isolated ischemic and reperfused rat heart.
Topics: Animals; Blood Pressure; Catalase; Deferoxamine; Female; Freezing; Glutathione Peroxidase; Heart Rat | 1993 |
Coronary vascular injury following transient coronary artery occlusion: prevention by pretreatment with deferoxamine, dimethylthiourea and N-2-mercaptoproprionyl glycine.
Topics: Animals; Capillary Permeability; Coronary Disease; Coronary Vessels; Deferoxamine; Dogs; Lipid Perox | 1993 |
Deferoxamine reduces the reperfusion injury in isolated neonatal rabbit hearts after hypothermic preservation.
Topics: Animals; Animals, Newborn; Cyclic N-Oxides; Deferoxamine; Electron Spin Resonance Spectroscopy; Free | 1993 |
Antiarrhythmic effects of ceruloplasmin during reperfusion in the ischemic isolated rat heart.
Topics: Animals; Anti-Arrhythmia Agents; Antioxidants; Ceruloplasmin; Deferoxamine; Dose-Response Relationsh | 1995 |
Effect of desferrioxamine cardioplegia on ischemia-reperfusion injury in isolated rat heart.
Topics: Animals; Deferoxamine; Diastole; Heart Arrest, Induced; Lactic Acid; Male; Microscopy, Electron; Myo | 1997 |
Effect of deferoxamine on post-hypoxic-ischemic reperfusion injury of the newborn lamb heart.
Topics: Animals; Animals, Newborn; Ascorbic Acid; Chelating Agents; Deferoxamine; Dehydroascorbic Acid; Fema | 1999 |
Promotion of copper excretion from the isolated rat heart attenuates postischemic cardiac oxidative injury.
Topics: Animals; Antidotes; Chelating Agents; Copper; Deferoxamine; Histidine; Male; Myocardial Ischemia; My | 1999 |
Warm and cold ischemia result in different mechanisms of injury to the coronary vasculature during reperfusion of rat hearts.
Topics: Animals; Blood Flow Velocity; Coronary Circulation; Deferoxamine; Free Radicals; Heart; Indomethacin | 2000 |
Quantification of hydroxyl radical and its lack of relevance to myocardial injury during early reperfusion after graded ischemia in rat hearts.
Topics: Animals; Coronary Disease; Deferoxamine; Free Radicals; Gentisates; Heart; Hydroxides; Hydroxybenzoa | 1992 |
Antiradical effects in L-propionyl carnitine protection of the heart against ischemia-reperfusion injury: the possible role of iron chelation.
Topics: Animals; Carnitine; Deferoxamine; Electron Spin Resonance Spectroscopy; Energy Metabolism; Free Radi | 1992 |
Deferoxamine, an iron chelator, reduces myocardial injury and free radical generation in isolated neonatal rabbit hearts subjected to global ischaemia-reperfusion.
Topics: Animals; Animals, Newborn; Catalase; Creatine Kinase; Deferoxamine; Electron Spin Resonance Spectros | 1992 |
Protective action of iron-chelating agents (catechol, mimosine, deferoxamine, and kojic acid) against ischemia-reperfusion injury of isolated neonatal rabbit hearts.
Topics: Animals; Animals, Newborn; Catechols; Creatine Kinase; Deferoxamine; Electron Spin Resonance Spectro | 1992 |
Efficacy and safety of deferoxamine conjugated to hydroxyethyl starch.
Topics: Animals; Coronary Disease; Deferoxamine; Edema; Hemodynamics; Hydroxyethyl Starch Derivatives; Lipid | 1992 |
Iron chelation in myocardial preservation after ischemia-reperfusion injury: the importance of pretreatment and toxicity.
Topics: Adenosine Triphosphate; Animals; Chelation Therapy; Deferoxamine; Dose-Response Relationship, Drug; | 1992 |
Age-related differences in cardiac susceptibility to ischemia/reperfusion injury. Response to deferoxamine.
Topics: Adenine Nucleotides; Aging; Animals; Animals, Newborn; Deferoxamine; Myocardial Contraction; Myocard | 1992 |
Postischemic free radical production in the venous blood of the regionally ischemic swine heart. Effect of deferoxamine.
Topics: Alcohols; Animals; Cyclic N-Oxides; Deferoxamine; Electron Spin Resonance Spectroscopy; Free Radical | 1991 |
Pretreatment with the iron chelator desferrioxamine fails to provide sustained protection against myocardial ischaemia-reperfusion injury.
Topics: Animals; Blood Pressure; Deferoxamine; Dogs; Echocardiography; Female; Iron; Male; Myocardial Infarc | 1991 |
Treatment with deferoxamine during ischemia improves functional and metabolic recovery and reduces reperfusion-induced oxygen radical generation in rabbit hearts.
Topics: Animals; Deferoxamine; Electron Spin Resonance Spectroscopy; Female; Free Radicals; Heart; Iron; Mag | 1991 |
Coronary venous retroinfusion of deferoxamine reduces infarct size in pigs.
Topics: Animals; Cardiac Catheterization; Coronary Vessels; Deferoxamine; Female; Free Radical Scavengers; I | 1991 |
Is iron sufficiency a risk factor in ischemic heart disease?
Topics: Coronary Disease; Deferoxamine; Free Radicals; Humans; Iron; Myocardial Reperfusion Injury; Oxygen; | 1991 |
Deferoxamine fails to improve postischemic cardiac function in hypertrophied hearts.
Topics: Animals; Cardiomegaly; Deferoxamine; Free Radical Scavengers; Myocardial Reperfusion; Myocardial Rep | 1990 |
Studies on the effects of antioxidants and inhibitors of radical generation on free radical production in the reperfused rat heart using electron spin resonance spectroscopy.
Topics: Allopurinol; Animals; Antioxidants; Catalase; Deferoxamine; Electron Spin Resonance Spectroscopy; Fr | 1990 |
Improvement of ischemic and postischemic mitochondrial function by deferrioxamine: the role of iron.
Topics: Animals; Coronary Disease; Cytosol; Deferoxamine; In Vitro Techniques; Iron; Male; Mitochondria, Hea | 1990 |
Iron-mediated radical reactions upon reperfusion contribute to myocardial "stunning".
Topics: Animals; Coronary Circulation; Cyclic N-Oxides; Deferoxamine; Dogs; Female; Free Radicals; Heart; He | 1990 |
Diltiazem and/or desferrioxamine administered at the time of reperfusion fail to improve post-ischemic recovery in the isolated rat heart after long-term hypothermic storage.
Topics: Adenosine Triphosphate; Animals; Cold Temperature; Creatine Kinase; Deferoxamine; Diltiazem; Heart; | 1990 |
The effect of desferal on rat heart mitochondrial function, iron content, and xanthine dehydrogenase/oxidase conversion during ischemia-reperfusion.
Topics: Animals; Deferoxamine; In Vitro Techniques; Iron; Male; Mitochondria, Heart; Myocardial Reperfusion | 1990 |
Effect of desferrioxamine on reperfusion damage of rat heart mitochondria.
Topics: Animals; Deferoxamine; Female; Male; Mitochondria, Heart; Myocardial Reperfusion Injury; Rats; Rats, | 1990 |
Inability of desferrioxamine to limit tissue injury in the ischaemic and reperfused rabbit heart.
Topics: Animals; Coronary Disease; Deferoxamine; Free Radicals; Hemodynamics; Hydroxides; Hydroxyl Radical; | 1989 |
Role of iron in postischemic microvascular injury.
Topics: Animals; Apoproteins; Capillary Permeability; Coronary Circulation; Deferoxamine; Iron; Male; Microc | 1989 |
Early treatment with deferoxamine limits myocardial ischemic/reperfusion injury.
Topics: Animals; Coronary Circulation; Coronary Vessels; Deferoxamine; Dogs; Female; Hemodynamics; Infusions | 1989 |
Amelioration of postischemic stunning by deferoxamine-blood cardioplegia.
Topics: Animals; Blood; Deferoxamine; Dogs; Free Radicals; Heart Arrest, Induced; Myocardial Contraction; My | 1989 |
Inactivation of creatine phosphokinase by superoxide during reperfusion injury.
Topics: Animals; Catalase; Cattle; Coronary Disease; Creatine Kinase; Deferoxamine; Disease Models, Animal; | 1988 |
[A new concept of cardioplegic protection in cardiac surgery: iron chelation].
Topics: Animals; Cardiac Surgical Procedures; Cardioplegic Solutions; Coronary Disease; Deferoxamine; Extrac | 1988 |